MY ACCOUNT | NEWSLETTER |

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test


VolitionRx Limited, a multinational epigenetics company, has inked a global agreement with Nu.Q Vet test. The global supply agreement makes VolitionRx the worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health.

According to a clinical study conducted by Volition and Texas A&M University researchers published in August 2022, the cancer test detected 76% of systemic cancers at 97% specificity versus control.

There are approximately 84 million pet dogs in the U.S. and just under 50% of dogs will have at least one veterinary care visit per year. Volition said in its news release that this provides an incredible opportunity to screen senior dogs over seven years of age and breeds at risk of cancer.

"The Nu.Q Vet Cancer Test was developed with the goal of providing an accessible and affordable screening test to aid early detection,” said Dr. Tom Butera, chief executive officer of Volition Veterinary Diagnostics Development LLC.

“This supply agreement is an exciting moment for Volition as we continue to commercialize our Nu.Q technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities,” he said.

About Volition

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com

Like1
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Sploot opens second clinic in Denver, with more on the way

Like0
Dislike0

Dr. Christopher Byers: The pandemic broke me

Like0
Dislike0

Disaster preparedness for animals

Like0
Dislike0

Echocardiographic indicators of fluid responsiveness in hospitalized dogs with compromised hemodynamics, tissue hypoperfusion

Like0
Dislike0

Morris Animal Foundation accepting RFPs to use golden retriever study data, samples

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2022 - All Rights Reserved
ISSN 2768-198X

Top